Department of Health Statistics, Public Health College, Inner Mongolia Medical University, Hohhot, PR China.
J Clin Hypertens (Greenwich). 2021 Nov;23(11):2016-2025. doi: 10.1111/jch.14375. Epub 2021 Oct 26.
The authors assessed treatment and control of blood glucose, blood pressure (BP), and blood lipids among patients from Inner Mongolia with diabetes mellitus (DM) and hypertension (HTN) and identified the modifiable factors associated with treatment and achievement of blood glucose, BP, and blood lipid targets. The authors used a multistage stratified cluster sampling method according to geographical location and level of economic development in Inner Mongolia. Among patients with DM and HTN, the crude rates of fasting plasma glucose (FPG) treatment and control was 30.76% and 4.73%, respectively. Crude rates of BP treatment and control were 50.81% and 8.70%, respectively. The authors found that treatment rates of HTN and DM and control rates of BP and FPG showed a gradually increasing trend with increased age. Among patients with DM and HTN, the likelihood of treatment for HTN and DM was significantly increased among participants who were older, non-Mongolian, male, obese, smokers, and those with previous cardiovascular disease. The authors found that control of BP, FPG, and low-density lipoprotein cholesterol was far from optimal among study participants. Medical and health departments in Inner Mongolia should take appropriate measures to reduce the burden of DM and HTN in the population, such as by promoting and improving the quality of HTN and DM treatment to achieve control goals and reduce the risk of cardiovascular disease.
作者评估了内蒙古糖尿病(DM)和高血压(HTN)患者的血糖、血压(BP)和血脂治疗和控制情况,并确定了与血糖、BP 和血脂目标治疗和达标相关的可改变因素。作者采用多阶段分层聚类抽样方法,根据地理位置和内蒙古经济发展水平进行抽样。在 DM 和 HTN 患者中,空腹血糖(FPG)治疗和控制的粗率分别为 30.76%和 4.73%。BP 治疗和控制的粗率分别为 50.81%和 8.70%。作者发现,HTN 和 DM 的治疗率以及 BP 和 FPG 的控制率随年龄的增加呈逐渐上升趋势。在 DM 和 HTN 患者中,年龄较大、非蒙古族、男性、肥胖、吸烟者以及有既往心血管疾病的患者,HTN 和 DM 的治疗可能性显著增加。作者发现,研究参与者的 BP、FPG 和低密度脂蛋白胆固醇的控制远不理想。内蒙古的医疗卫生部门应采取适当措施,减轻人群中 DM 和 HTN 的负担,例如通过促进和提高 HTN 和 DM 的治疗质量来实现控制目标,降低心血管疾病风险。